These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3180632)

  • 1. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.
    Cook JA; Smith DE; Cornish LA; Tankanow RM; Nicklas JM; Hyneck ML
    Clin Pharmacol Ther; 1988 Nov; 44(5):487-500. PubMed ID: 3180632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with chronic renal failure.
    Lau HS; Hyneck ML; Berardi RR; Swartz RD; Smith DE
    Clin Pharmacol Ther; 1986 Jun; 39(6):635-45. PubMed ID: 3709028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of acute tolerance to bumetanide: bolus injection studies.
    Cook JA; Smith DE
    Pharm Res; 1987 Oct; 4(5):379-84. PubMed ID: 3508546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure.
    Vargo DL; Kramer WG; Black PK; Smith WB; Serpas T; Brater DC
    Clin Pharmacol Ther; 1995 Jun; 57(6):601-9. PubMed ID: 7781259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bumetanide and furosemide in heart failure.
    Brater DC; Day B; Burdette A; Anderson S
    Kidney Int; 1984 Aug; 26(2):183-9. PubMed ID: 6503136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the variability in the pharmacokinetics and pharmacodynamics of bumetanide in critically ill infants.
    Sullivan JE; Witte MK; Yamashita TS; Myers CM; Blumer JL
    Clin Pharmacol Ther; 1996 Oct; 60(4):414-23. PubMed ID: 8873689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease.
    Marcantonio LA; Auld WH; Murdoch WR; Purohit R; Skellern GG; Howes CA
    Br J Clin Pharmacol; 1983 Feb; 15(2):245-52. PubMed ID: 6849758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bumetanide and furosemide.
    Brater DC; Chennavasin P; Day B; Burdette A; Anderson S
    Clin Pharmacol Ther; 1983 Aug; 34(2):207-13. PubMed ID: 6872415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of food on the absorption of frusemide and bumetanide in man.
    McCrindle JL; Li Kam Wa TC; Barron W; Prescott LF
    Br J Clin Pharmacol; 1996 Dec; 42(6):743-6. PubMed ID: 8971430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrolyte excretion patterns. Intravenous and oral doses of bumetanide compared to furosemide.
    Brater DC; Fox WR; Chennavasin P
    J Clin Pharmacol; 1981; 21(11):599-603. PubMed ID: 7338569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and diuretic effect after administration of retarded capsules of bumetanide in human subjects.
    Yagi N; Kiuchi T; Satoh H; Ishikawa Y; Takada M; Sekikawa H
    Biol Pharm Bull; 1999 Mar; 22(3):275-80. PubMed ID: 10220284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy.
    Rudy DW; Voelker JR; Greene PK; Esparza FA; Brater DC
    Ann Intern Med; 1991 Sep; 115(5):360-6. PubMed ID: 1863026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure.
    Ter Maaten JM; Rao VS; Hanberg JS; Perry Wilson F; Bellumkonda L; Assefa M; Sam Broughton J; D'Ambrosi J; Wilson Tang WH; Damman K; Voors AA; Ellison DH; Testani JM
    Eur J Heart Fail; 2017 Aug; 19(8):1014-1022. PubMed ID: 28105769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bumetanide in congestive heart failure.
    Kourouklis C; Christensen O; Augoustakis D
    Curr Med Res Opin; 1976; 4(6):422-31. PubMed ID: 793779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of duration of diuretic effect in preventing sodium retention.
    Ferguson JA; Sundblad KJ; Becker PK; Gorski JC; Rudy DW; Brater DC
    Clin Pharmacol Ther; 1997 Aug; 62(2):203-8. PubMed ID: 9284857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of enalapril in congestive heart failure.
    Dickstein K
    Drugs; 1986; 32 Suppl 5():40-4. PubMed ID: 3032562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.
    Ward A; Heel RC
    Drugs; 1984 Nov; 28(5):426-64. PubMed ID: 6391889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of torasemide in congestive heart failure.
    Kramer WG
    Cardiology; 1994; 84 Suppl 2():108-14. PubMed ID: 7954532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of enalapril in hospitalized patients with congestive heart failure.
    Dickstein K; Till AE; Aarsland T; Tjelta K; Abrahamsen AM; Kristianson K; Gomez HJ; Gregg H; Hichens M
    Br J Clin Pharmacol; 1987 Apr; 23(4):403-10. PubMed ID: 3034316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.